The place Sage Therapeutics Stands With Analysts – Sage Therapeutics (NASDAQ:SAGE)

Throughout the latest three months, 14 analysts have shared their insights on Sage Therapeutics SAGE, expressing quite a lot of opinions spanning from bullish to bearish.

Within the desk beneath, you will discover a abstract of their latest scores, revealing the shifting sentiments over the previous 30 days and evaluating them to the earlier months.

	Bullish	Considerably Bullish	Detached	Considerably Bearish	Bearish
Whole Rankings	0	2	10	2	0
Final 30D	0	0	1	0	0
1M In the past	0	0	3	0	0
2M In the past	0	2	3	0	0
3M In the past	0	0	3	2	0

The 12-month worth targets assessed by analysts reveal additional insights, that includes a median goal of $11.07, a excessive estimate of $26.00, and a low estimate of $4.00. A detrimental shift in sentiment is clear as analysts have decreased the common worth goal by 30.2%.

Deciphering Analyst Rankings: A Nearer Look

The standing of Sage Therapeutics amongst monetary consultants turns into clear with a radical evaluation of latest analyst actions. The abstract beneath outlines key analysts, their latest evaluations, and changes to scores and worth targets.

Analyst	Analyst Agency	Motion Taken	Ranking	Present Value Goal	Prior Value Goal
Paul Matteis	Stifel	Lowers	Maintain	$6.00	$10.00
Ritu Baral	TD Cowen	Lowers	Maintain	$9.00	$10.00
Brian Abrahams	RBC Capital	Maintains	Sector Carry out	$4.00	$4.00
Douglas Tsao	HC Wainwright & Co.	Maintains	Impartial	$14.00	$14.00
George Farmer	Scotiabank	Lowers	Sector Outperform	$14.00	$17.00
Yasmeen Rahimi	Piper Sandler	Lowers	Chubby	$26.00	$52.00
Jay Olson	Oppenheimer	Lowers	Carry out	$8.00	$9.00
Joon Lee	Truist Securities	Lowers	Maintain	$8.00	$13.00
Douglas Tsao	HC Wainwright & Co.	Lowers	Impartial	$14.00	$25.00
Tazeen Ahmad	B of A Securities	Lowers	Underperform	$6.00	$11.00
Laura Chico	Wedbush	Lowers	Impartial	$8.00	$9.00
Joel Beatty	Baird	Lowers	Impartial	$9.00	$13.00
Douglas Tsao	HC Wainwright & Co.	Maintains	Impartial	$25.00	$25.00
Brian Abrahams	RBC Capital	Lowers	Underperform	$4.00	$10.00

Key Insights:

• Motion Taken: Analysts reply to modifications in market situations and firm efficiency, continuously updating their suggestions. Whether or not they ‘Preserve’, ‘Elevate’ or ‘Decrease’ their stance, IT displays their response to latest developments associated to Sage Therapeutics. This Information presents a snapshot of how analysts understand the present state of the corporate.
• Ranking: Analysts assign qualitative assessments to shares, starting from ‘Outperform’ to ‘Underperform’. These scores convey the analysts’ expectations for the relative efficiency of Sage Therapeutics in comparison with the broader market.
• Value Targets: Understanding forecasts, analysts provide estimates for Sage Therapeutics’s future worth. Analyzing the present and prior targets gives perception into analysts’ altering expectations.

Assessing these analyst evaluations alongside essential monetary indicators can present a complete overview of Sage Therapeutics’s market place. Keep knowledgeable and make well-judged choices with the help of our Rankings Desk.

Keep updated on Sage Therapeutics analyst scores.

In case you are eager about following small-cap inventory information and efficiency you can begin by monitoring IT right here.

Unveiling the Story Behind Sage Therapeutics

Sage Therapeutics Inc is a clinical-stage biopharmaceutical firm targeted on mind Health medicines. The corporate is focusing on ailments and issues of the mind with three key focus areas: melancholy, neurology and neuropsychiatry; additionally focusing on two essential central nervous system, or CNS, receptor programs, GABA and NMDA. Its merchandise ZURZUVAE is a medication for the remedy of postpartum melancholy, or PPD, in adults, and ZULRESSO is a CIV injection for the remedy of postpartum melancholy in people 15 years outdated and older. IT additionally has different medicine in its pipeline comparable to SAGE-324, Dalzanemdor (SAGE-718) amongst others.

Monetary Milestones: Sage Therapeutics’s Journey

Market Capitalization: Indicating a lowered dimension in comparison with trade averages, the corporate’s market capitalization poses distinctive challenges.

Income Progress: Over the three months interval, Sage Therapeutics showcased optimistic efficiency, reaching a income progress price of 337.08% as of 30 September, 2024. This displays a considerable enhance within the firm’s top-line earnings. When in comparison with others within the Health Care sector, the corporate excelled with a progress price increased than the common amongst friends.

Web Margin: Sage Therapeutics’s web margin excels past trade benchmarks, reaching -788.06%. This signifies environment friendly price administration and powerful monetary Health.

Return on Fairness (ROE): Sage Therapeutics’s monetary energy is mirrored in its distinctive ROE, which exceeds trade averages. With a outstanding ROE of -15.86%, the corporate showcases environment friendly use of fairness capital and powerful monetary Health.

Return on Property (ROA): Sage Therapeutics’s ROA is beneath trade averages, indicating potential challenges in effectively using belongings. With an ROA of -14.18%, the corporate could face hurdles in reaching optimum monetary returns.

Debt Administration: Sage Therapeutics’s debt-to-equity ratio is beneath the trade common at 0.02, reflecting a decrease dependency on debt financing and a extra conservative monetary strategy.

What Are Analyst Rankings?

Rankings come from analysts, or specialists inside banking and monetary programs that report for particular shares or outlined sectors (sometimes as soon as per quarter for every inventory). Analysts often derive their Information from firm convention calls and conferences, monetary statements, and conversations with vital insiders to succeed in their choices.

Analysts could improve their evaluations by incorporating forecasts for metrics like progress estimates, earnings, and income, delivering further steering to traders. IT is important to acknowledge that, though consultants in shares and sectors, analysts are human and specific their opinions when offering insights.

Which Shares Are Analysts Recommending Now?

Benzinga Edge provides you prompt entry to all main analyst upgrades, downgrades, and worth targets. Type by accuracy, upside potential, and extra. Click on right here to remain forward of the market.

This text was generated by Benzinga’s automated content material engine and reviewed by an editor.